Basilea Pharmaceutica (PK5) Stock Overview
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PK5 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Basilea Pharmaceutica AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 53.20 |
| 52 Week High | CHF 63.70 |
| 52 Week Low | CHF 48.15 |
| Beta | 0.41 |
| 1 Month Change | -11.19% |
| 3 Month Change | -1.48% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| PK5 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.4% | -0.5% | -0.9% |
| 1Y | n/a | -3.9% | 1.9% |
Return vs Industry: Insufficient data to determine how PK5 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how PK5 performed against the German Market.
Price Volatility
| PK5 volatility | |
|---|---|
| PK5 Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in DE Market | 13.4% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: PK5 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: PK5's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 189 | David Veitch | www.basilea.com |
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold infections; ceftibuten-ledaborbactam etzadroxil, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe enterobacteriaceae infections.
Basilea Pharmaceutica AG Fundamentals Summary
| PK5 fundamental statistics | |
|---|---|
| Market cap | €679.04m |
| Earnings (TTM) | €43.74m |
| Revenue (TTM) | €252.57m |
Is PK5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PK5 income statement (TTM) | |
|---|---|
| Revenue | CHF 232.38m |
| Cost of Revenue | CHF 145.22m |
| Gross Profit | CHF 87.16m |
| Other Expenses | CHF 46.92m |
| Earnings | CHF 40.24m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 18, 2026
| Earnings per share (EPS) | 3.25 |
| Gross Margin | 37.51% |
| Net Profit Margin | 17.32% |
| Debt/Equity Ratio | 59.0% |
How did PK5 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/17 19:51 |
| End of Day Share Price | 2026/06/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Basilea Pharmaceutica AG is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brigitte de Lima | BofA Global Research |
| Brian White | Calvine Partners LLP |
| Andrew Keith | Calvine Partners LLP |